Rickman, David S.

Publications

Sort by

Co-Author Network

selected publications

Distinct mesenchymal cell states mediate prostate cancer progression. bioRxiv : the preprint server for biology. 2023 Article GET IT
Defining cellular population dynamics at single-cell resolution during prostate cancer progression. eLife. 2022 Academic Article GET IT
AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer. eLife. 2022 Academic Article GET IT
Times cited: 4
Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors. Advanced materials (Deerfield Beach, Fla.). 2021 Academic Article GET IT
Times cited: 16
RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer. Cancer research. 2021 Academic Article GET IT
Times cited: 9
Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nature communications. 2021 Academic Article GET IT
Times cited: 21
Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. NPJ precision oncology. 2021 Academic Article GET IT
Times cited: 224
Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 36
N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. The Journal of clinical investigation. 2019 Academic Article GET IT
Times cited: 84
Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target. Neoplasia (New York, N.Y.). 2019 Academic Article GET IT
Times cited: 13
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Science translational medicine. 2019 Academic Article GET IT
Times cited: 83
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 130
The Expanding World of N-MYC-Driven Tumors. Cancer discovery. 2018 Review GET IT
Times cited: 134
Association with Aurora-A Controls N-MYC-Dependent Promoter Escape and Pause Release of RNA Polymerase II during the Cell Cycle. Cell reports. 2017 Academic Article GET IT
Times cited: 43
Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network. Genome biology. 2017 Academic Article GET IT
Times cited: 23
Biology and evolution of poorly differentiated neuroendocrine tumors. Nature medicine. 2017 Academic Article GET IT
Times cited: 126
A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents. Cold Spring Harbor molecular case studies. 2017 Academic Article GET IT
Times cited: 20
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer cell. 2016 Academic Article GET IT
Times cited: 327
A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors. Cell reports. 2016 Academic Article GET IT
Times cited: 23
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA oncology. 2015 Academic Article GET IT
Times cited: 216
ERG induces taxane resistance in castration-resistant prostate cancer. Nature communications. 2014 Academic Article GET IT
Times cited: 91
Aggressive variants of castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Review GET IT
Times cited: 285
CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features. Haematologica. 2013 Academic Article GET IT
Times cited: 53
Oncogenic transcription factors as master regulators of chromatin topology: a new role for ERG in prostate cancer. Cell cycle (Georgetown, Tex.). 2012 Academic Article GET IT
Times cited: 11
Next-generation prostate cancer biobanking: toward a processing protocol amenable for the International Cancer Genome Consortium. Diagnostic molecular pathology : the American journal of surgical pathology, part B. 2012 Academic Article GET IT
Times cited: 24
Oncogene-mediated alterations in chromatin conformation. Proceedings of the National Academy of Sciences of the United States of America. 2012 Academic Article GET IT
Times cited: 110
Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. Proceedings of the National Academy of Sciences of the United States of America. 2012 Academic Article GET IT
Times cited: 40
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer discovery. 2011 Academic Article GET IT
Times cited: 633
Biobanking after robotic-assisted radical prostatectomy: a quality assessment of providing prostate tissue for RNA studies. Journal of translational medicine. 2011 Academic Article GET IT
Times cited: 24
Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urologic oncology. 2011 Academic Article GET IT
Times cited: 150
ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia (New York, N.Y.). 2010 Academic Article GET IT
Times cited: 51
Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome research. 2010 Academic Article GET IT
Times cited: 157
An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. Molecular cancer. 2010 Academic Article GET IT
Times cited: 35
Biological and clinical relevance of transcriptionally active human papillomavirus (HPV) infection in oropharynx squamous cell carcinoma. International journal of cancer. 2010 Academic Article GET IT
Times cited: 176
ERG rearrangement metastasis patterns in locally advanced prostate cancer. Urology. 2010 Academic Article GET IT
Times cited: 49
In situ evidence of KRAS amplification and association with increased p21 levels in non-small cell lung carcinoma. American journal of clinical pathology. 2009 Academic Article GET IT
Times cited: 19
WNT/beta-catenin pathway activation in Wilms tumors: a unifying mechanism with multiple entries?. Genes, chromosomes & cancer. 2009 Academic Article GET IT
Times cited: 44
N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia (New York, N.Y.). 2009 Academic Article GET IT
Times cited: 103
Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes, chromosomes & cancer. 2009 Academic Article GET IT
Times cited: 83
SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer research. 2009 Academic Article GET IT
Times cited: 162
Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 298
Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer cell. 2008 Academic Article GET IT
Times cited: 348
Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays. Oncogene. 2008 Academic Article GET IT
Times cited: 123
The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia. 2008 Academic Article GET IT
Times cited: 90
EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia (New York, N.Y.). 2008 Academic Article GET IT
Times cited: 222
Stabilization of beta-catenin affects mouse embryonic liver growth and hepatoblast fate. Hepatology (Baltimore, Md.). 2008 Academic Article GET IT
Times cited: 121
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS medicine. 2007 Academic Article GET IT
Times cited: 141
The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007 Academic Article GET IT
Times cited: 484
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (Baltimore, Md.). 2007 Academic Article GET IT
Times cited: 886
Pre-TCR expression cooperates with TEL-JAK2 to transform immature thymocytes and induce T-cell leukemia. Blood. 2006 Academic Article GET IT
Times cited: 30
Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood. 2006 Academic Article GET IT
Times cited: 169
Apc tumor suppressor gene is the "zonation-keeper" of mouse liver. Developmental cell. 2006 Academic Article GET IT
Times cited: 394
Comparison of the latest commercial short and long oligonucleotide microarray technologies. BMC genomics. 2006 Academic Article GET IT
Times cited: 44
Optimizing spotting solutions for increased reproducibility of cDNA microarrays. Nucleic acids research. 2003 Academic Article GET IT
Times cited: 45
Profiling of pathway-specific changes in gene expression following growth of human cancer cell lines transplanted into mice. Genome biology. 2003 Academic Article GET IT
Times cited: 43
Microarray-based method for combinatorial library sequence mapping and characterization. BioTechniques. 2003 Academic Article GET IT
Times cited: 3
Integrating cancer genomics and proteomics in the post-genome era. Proteomics. 2002 Academic Article GET IT
Times cited: 99
Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer research. 2001 Academic Article GET IT
Times cited: 313
The gene for the axonal cell adhesion molecule TAX-1 is amplified and aberrantly expressed in malignant gliomas. Cancer research. 2001 Academic Article GET IT
Times cited: 25

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

"DNMT and TET1 reprogramming as a targetable mechanism of resistance in advanced prostate cancer" awarded by National Cancer Institute Principal Investigator 2023 - 2028
Defining Molecular Determinants of Lineage Plasticity as a Mechanism of Treatment Resistance in Prostate Cancer awarded by National Cancer Institute Principal Investigator 2019 - 2024
Development of Next-Generation Therapeutics for Advanced Prostate Cancer awarded by Chimerix, Inc. Principal Investigator 2022 - 2023
Temporal Evolution of N-Myc Signalign and Early Targeting of the Neuroendocrine Phenotype in Prostate Cancer awarded by United States Department of Defense Principal Investigator 2017 - 2023

Interplay of DNA methylation and histone methylation driving neuroendocrine phenotype in advanced prostate cancer awarded by United States Department of Defense Key Personnel 2021 - 2024
Transferrin Receptor Identifies a Comprehensive pool of Circulating Tumor Cells with unique molecular features from metastatic Prostate Cancer Patients awarded by United States Department of Defense Key Personnel 2019 - 2023
Weill Cornell Medicine (WCM) SPORE in Prostate Cancer awarded by National Cancer Institute Key Personnel 2017 - 2023

NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer awarded by National Cancer Institute Principal Investigator Subaward 2019 - 2023

more ...

less ...

Background

education and training

Ph.D., Mount Sinai School of Medicine 1997
B.S., Baylor University 1989

Contact

full name

David S. Rickman

primary email

dsr2005@med.cornell.edu

VIVO Weill Cornell Medical College

David S. Rickman Associate Professor of Pathology and Laboratory Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email